Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors

Learn more about:
Related Clinical Trial
Induction of Cortical Plasticity S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer Laser Interstitial Thermal Therapy (LITT) for the Treatment of Pediatric Central Nervous System Tumors Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Comparing Immobilisation Shells in Cranial Radiotherapy FBY PET/CT in Patients With Brain Tumors Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma Longitudinal Metabolomic and Epigenetic Profiling of Bodyfluids From Patients With Lung and Brain Cancer Receiving Radiation Therapy Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Prevalence of Post-craniotomy Headache in Siriraj Hospital Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma Wise Cortical Strip for Intraoperative Neurophysiological Monitoring Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI) A Study of Cognitive Changes in Patients Receiving Brain Radiation

Brief Title

Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors

Official Title

Diagnostic Assessment Study, Single Site and Prospective, comparing18F-DOPA PET and Multiparametric RMI in Initial Exploration of Diffuse Glial Tumors

Brief Summary

      For patient having a brain tumor, RMI is the standard exam for tumor characterization and
      determines initial surgery.

      The aim of this study is to assess if PET could provide additional information that could
      have an impact on surgery (indication and planification)
    



Study Type

Interventional


Primary Outcome

PET pictures and MRI sequences comparison


Condition

Brain Neoplasms

Intervention

PET imagery

Study Arms / Comparison Groups

 PET Arm
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Diagnostic Test

Estimated Enrollment

16

Start Date

June 12, 2018

Completion Date

September 11, 2019

Primary Completion Date

September 11, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Suspected glial resectable tumor

          -  Free and informed consent

          -  Affiliated to French social security

        Exclusion Criteria:

          -  Suspected high grade glioma

          -  Surgical emergency

          -  Pregnant or breastfeeding woman

          -  Patient deprived of their liberty or under guardianship

          -  Patient not able to follow study medical monitoring for geographical, social or
             psychological reasons

          -  Treated with carbidopa, catechol-O-methyl transferase inhibitor, haloperidol,
             reserpine within 2 weeks before PET imagery
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Florence LE JEUNE, Professor, , 

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT03525080

Organization ID

2017-4-52-010


Responsible Party

Sponsor

Study Sponsor

Center Eugene Marquis


Study Sponsor

Florence LE JEUNE, Professor, Principal Investigator, Centre Eugène Marquis


Verification Date

January 2020